Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2008

View Archived Issues

Pim-2 kinase inhibitors identified as potential drugs for the treatment of inflammation

CB2 ligands developed at Abbott undergoing optimization

Urotensin-II receptor antagonist optimization leads to JNJ-39327041

Characterization of Pfizer's novel CP-690550 in de novo kidney transplant patients

Novel antiviral agents claimed by Novartis

Oncothyreon presents update on clinical development activities

Chelsea Therapeutics initiates patient dosing in Study 301 phase III trial of droxidopa in NOH

Neurocrine presents elagolix PETAL study results in endometriosis

FDA approves Sandoz's Omnitrope Pen 10 with liquid cartridge for growth hormone deficiency

PHA-848125, a novel CDK inhibitor orally active in preclinical model of ovarian carcinoma

Ikaria acquires North American rights to Lucassin for HRS from Orphan Therapeutics

Refinement of H3 receptor antagonists for wakefulness continues at Arena Pharmaceuticals

Wyeth advances synthesis of dual selective serotonin reuptake inhibitors/5-HT1A antagonists

Diffusion initiates phase I/II trans-sodium crocetinate trial in patients with PAD

Recent patents cover novel anticancer agents

OSI initiates clinical development program for antidiabetes candidate, PSN-821

Plexxikon commences phase I trial for novel kinase inhibitor, PLX-5568

New immunmodulatory agents disclosed by Otsuka Chemical

Sangamo BioSciences initiates phase II trial for SB-509 in ALS

Agile achieves phase II study endpoints with low-dose contraceptive patch

Phase II study shows Arcalyst reduces gout flares by 81%

OncoGenex grants Eagle Pharmaceuticals exclusive worldwide rights to Tocosol paclitaxel

Anavex successfully completes preclinical studies of ANAVEX 2-73 in Alzheimer's disease

Dako acquires InstrumeC

ZymoGenetics and Merck Serono restructure 2001 partnership agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...